Medtronic plc announced positive results from verification studies of its investigational Nellcor™ pulse oximetry technology, featuring the Nell-EQ™ intelligent processor. The studies demonstrated that the technology achieved SpO₂ accuracy surpassing the FDA's draft-recommended threshold and pulse rate accuracy within the Nellcor™ acceptance limits, across a full range of skin tones. The technology, which previously received FDA Safer Technologies Program (STeP) designation, is currently under 510(k) review. The results were presented at the Society for Technology in Anesthesia (STA) Annual Meeting 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on January 20, 2026, and is solely responsible for the information contained therein.